Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06297954
Other study ID # GA22-00011
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 16, 2023
Est. completion date June 2024

Study information

Verified date February 2024
Source Universidad Autonoma de Nuevo Leon
Contact José Luis Herrera Elizondo, Physician
Phone +528180182968
Email here_herrera_11@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, randomized, double-blind study will be conducted, including all patients with upper gastrointestinal bleeding, defined as vomiting blood or black bowel movements, within 12 hours prior to admission. Patients will be randomized to receive intravenous metoclopramide 20 mg or placebo, a placebo is a look-alike substance that contains no active drug. Then endoscopy will be performed in the following 120 minutes, evaluating endoscopic visualization with the modified Avgerinos scale.


Description:

A prospective, longitudinal, randomized, double-blind study will be carried out in which all patients who come to the University Hospital "Dr. José Eleuterio González" with upper gastrointestinal tract bleeding, defined in our study as hematemesis or melena, including patients with this condition in the 12 hours prior to admission. Patients will be randomized to receive metoclopramide 20 mg IV or placebo, this randomization will be performed by means of a computer sequence to receive each of the treatment sequences. Subsequently, the upper endoscopy will be performed in the following 120 minutes, and the endoscopic visualization will be evaluated by the physician performing the procedure by means of the modified Avgerinos scale; which gives a score of 0-2 according to the percentage of mucosal vision; 0= <25% visible surface, 1= 25%-75% visible surface and 2= >75% visible surface, evaluating fundus, body, antrum and bulb, a score ≥ 6 will be considered a clean stomach and a score ≤ 5 will be considered full stomach. The diagnosis of origin of the upper gastrointestinal tract bleeding will be determined by the physician in charge of performing the endoscopy. All cases will be filmed and another physician will review the cases and validate the Avgerinos score, as well as the final diagnosis reported.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Hospitalized patients =18 years of age with variceal and non-variceal upper gastrointestinal tract bleeding (hematemesis and/or melena). - =12 hours of bleeding evolution. - Hemodynamic stability at the time of upper endoscopy. Exclusion Criteria: - Patients <18 years old. - Pregnant patients. - Metoclopramide allergy. - Refusal to be part of the study protocol.

Study Design


Intervention

Drug:
Metoclopramide
Patients will receive metoclopramide 20 mg IV in a single dose prior to randomization.
Placebo
Patients will receive placebo 10 ml IV in a single dose prior to randomization.

Locations

Country Name City State
Mexico Hospital Universitario Dr. José Eleuterio González, UANL Monterrey Nuevo León

Sponsors (1)

Lead Sponsor Collaborator
Universidad Autonoma de Nuevo Leon

Country where clinical trial is conducted

Mexico, 

References & Publications (1)

Estes DJ, Berera S, Deshpande AR, Sussman DA. Re-Visiting Metoclopramide to Optimize Visualization with Gastrointestinal Bleeding - Mobilizing Existing Data. Clin Endosc. 2019 Sep;52(5):516-517. doi: 10.5946/ce.2019.046. Epub 2019 Jul 16. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the usefulness of metoclopramide in improving endoscopic visualisation in patients with upper gastrointestinal bleeding. Using modified Avgerinos scale; which gives a score of 0-2 according to the percentage of mucosal vision; 0 = <25% visible surface, 1 = 25%-75% visible surface and 2= >75% visible surface, evaluating fundus, body, antrum and bulb, a score = 6 will be considered a clean stomach and a score = 5 will be considered full stomach. From admission to discharge for up to 5 days, during this time their clinical condition will be evaluated, through a general physical examination, taking vital signs and questioning them about possible side effects associated with metoclopramide
Secondary To determine whether the use of metoclopramide avoids repeating the endoscopic procedure. The need to repeat the endoscopic procedure will be evaluated in case clinical data of new bleeding from the digestive tract, evidenced by melena or hematemesis is found. From admission to discharge for up to 5 days, during this time it will be evaluated the need for new endoscopy in case clinical data of new bleeding from the digestive tract evidenced by melena or hematemesis.
Secondary To determine whether the use of metoclopramide shortens the length of hospital stay. The days of hospital stay will be counted and comparing both arms. From admission to discharge for up to 30 days, during this time their clinical condition will be evaluated, through a general physical examination, taking vital signs and questioning them about possible side effects associated with metoclopramide.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02537353 - Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Phase 4
Recruiting NCT03624517 - Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices Phase 4
Suspended NCT03337256 - Direct Discharge of Patients With Upper Gastrointestinal Bleeding From the Emergency Department After Endoscopy N/A
Completed NCT04472364 - HemoPill Acute ® in Suspected Nonvariceal Upper Gastrointestinal Bleeding N/A
Completed NCT05563714 - Anticoagulation With Enhanced Gastrointestinal Safety N/A
Recruiting NCT00414713 - Transfusion Requirements in Gastrointestinal (GI) Bleeding Phase 4
Completed NCT03680950 - Efficacy Test of Real-Time Upper Gastrointestinal Monitoring System N/A
Completed NCT05085405 - Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial N/A
Recruiting NCT06077916 - Gastric CLEANsing by Intravenous AZithromycin in Urgent Endoscopy N/A
Recruiting NCT04902248 - OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding N/A
Completed NCT02446678 - Use of PillCam ESO2 in Triaging Patients Present With Upper GIB N/A
Completed NCT05631639 - Detection of Upper Gastrointestinal (GI) Bleeding Using a Novel Bleeding Sensor Capsule -A Pilot Study N/A
Completed NCT02978391 - UI-EWD for Endoscopic Hemostasis of Bleeding Peptic Ulcers and Bleeding After EMR/ESD N/A
Completed NCT00045799 - Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill Phase 3
Recruiting NCT03090945 - Pediatric Acute Gastrointestinal Bleeding Registry
Recruiting NCT06192355 - Single-use Versus Reusable Gastroscopes in Patients With Upper Gastrointestinal Bleeding. N/A
Recruiting NCT03785080 - Non-warfarin Oral AntiCoagulant Resumption After Gastrointestinal Bleeding in Atrial Fibrillation Patients N/A
Completed NCT03667703 - Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease Phase 4
Terminated NCT02017379 - Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed. N/A
Completed NCT01155401 - Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding N/A